{"hands_on_practices": [{"introduction": "Managing Parkinson's disease often involves complex polypharmacy. To standardize and compare different drug regimens, clinicians use the Levodopa Equivalent Daily Dose (LEDD) as a common metric that quantifies the total dopaminergic medication load. This first exercise provides foundational practice in calculating the LEDD from a typical multi-drug regimen, a core skill for accurately assessing a patient's therapy and guiding adjustments [@problem_id:4880907].", "problem": "A clinician seeks to quantify the total dopaminergic exposure for a patient with Parkinson’s disease using the levodopa equivalent daily dose (LEDD). The LEDD is defined as the sum of the daily oral levodopa dose plus the contributions of other dopaminergic agents converted into an equivalent amount of levodopa using widely accepted equivalence factors from clinical literature. For the following regimen, compute the total LEDD.\n\nThe regimen is: levodopa/carbidopa $100/25$ $\\mathrm{mg}$ four times daily, entacapone $200$ $\\mathrm{mg}$ taken with each levodopa dose, rasagiline $1$ $\\mathrm{mg}$ once daily, and pramipexole immediate-release $0.75$ $\\mathrm{mg}$ twice daily. Use the following well-tested equivalence facts:\n- Immediate-release levodopa dose contributes directly to LEDD: each $\\mathrm{mg}$ of levodopa contributes $1$ $\\mathrm{mg}$ LEDD.\n- Entacapone (Catechol-O-methyltransferase (COMT) inhibitor) at $200$ $\\mathrm{mg}$ co-administered with a levodopa dose increases the effective levodopa exposure for that dose; equivalently, the daily LEDD contribution from entacapone equals $0.33$ times the total daily levodopa administered with entacapone.\n- Rasagiline (monoamine oxidase-B (MAO-B) inhibitor) at $1$ $\\mathrm{mg}$ daily contributes $100$ $\\mathrm{mg}$ LEDD.\n- Pramipexole immediate-release contributes LEDD of $100$ times its total daily dose in $\\mathrm{mg}$.\n\nExpress the final LEDD in $\\mathrm{mg}$ and round your answer to four significant figures.", "solution": "The problem requires the calculation of the total levodopa equivalent daily dose (LEDD) for a patient on a specific multi-drug regimen for Parkinson's disease. The process begins with a rigorous validation of the problem statement.\n\n### Step 1: Extract Givens\n\nThe following data and definitions are explicitly provided:\n- **Patient Regimen:**\n  - Levodopa/carbidopa: $100/25 \\, \\mathrm{mg}$, administered four times daily.\n  - Entacapone: $200 \\, \\mathrm{mg}$, taken with each levodopa dose.\n  - Rasagiline: $1 \\, \\mathrm{mg}$, once daily.\n  - Pramipexole immediate-release (IR): $0.75 \\, \\mathrm{mg}$, twice daily.\n- **LEDD Definition:** The LEDD is the sum of the daily oral levodopa dose plus the contributions of other dopaminergic agents converted into an equivalent amount of levodopa.\n- **Equivalence Factors:**\n  - Immediate-release levodopa: Each $1 \\, \\mathrm{mg}$ of levodopa contributes $1 \\, \\mathrm{mg}$ to the LEDD.\n  - Entacapone ($200 \\, \\mathrm{mg}$ co-administered): The daily LEDD contribution equals $0.33$ times the total daily levodopa administered with entacapone.\n  - Rasagiline ($1 \\, \\mathrm{mg}$ daily): Contributes a fixed amount of $100 \\, \\mathrm{mg}$ to the LEDD.\n  - Pramipexole IR: The LEDD contribution is $100$ times its total daily dose in $\\mathrm{mg}$.\n- **Required Output Format:** The final answer for the LEDD must be expressed in $\\mathrm{mg}$ and rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem is assessed for validity against established criteria.\n- **Scientifically Grounded:** The problem is grounded in the principles of clinical pharmacology and neurology. The concept of LEDD is a standard, widely-used tool for quantifying dopaminergic medication load in the management of Parkinson's disease. The conversion factors provided are consistent with those found in clinical literature (e.g., Tomlinson et al., *Movement Disorders*, 2010), even though slight variations exist across different sources. The problem specifies a set of \"well-tested\" factors, making it self-contained. The dosages and medications are standard.\n- **Well-Posed:** The problem is well-posed. All necessary information—dosages, frequencies, and specific conversion factors—is provided to calculate a single, unique numerical value for the total LEDD.\n- **Objective:** The language is precise and quantitative, free of subjective or ambiguous terminology.\n\nThe problem does not exhibit any flaws such as scientific unsoundness, missing information, or logical contradiction. It is a formalizable and solvable problem based on established clinical practice.\n\n### Step 3: Verdict and Action\n\nThe problem is deemed **valid**. A full solution will be provided.\n\n### Solution Derivation\n\nThe total LEDD, denoted as $\\text{LEDD}_{\\text{total}}$, is the sum of the contributions from each component of the medication regimen. The problem states that the LEDD is the \"sum of the daily oral levodopa dose plus the contributions of other dopaminergic agents\". This can be expressed as:\n$$ \\text{LEDD}_{\\text{total}} = (\\text{direct levodopa contribution}) + (\\text{entacapone contribution}) + (\\text{rasagiline contribution}) + (\\text{pramipexole contribution}) $$\nWe will calculate each term separately.\n\n1.  **Direct Levodopa Contribution ($\\text{LEDD}_{L}$):**\n    The patient takes levodopa/carbidopa $100/25 \\, \\mathrm{mg}$. The levodopa component is $100 \\, \\mathrm{mg}$ per dose. The carbidopa component is a peripheral decarboxylase inhibitor and does not contribute to the LEDD.\n    The daily dose of levodopa, $D_{L}$, is:\n    $$ D_{L} = 100 \\, \\frac{\\mathrm{mg}}{\\mathrm{dose}} \\times 4 \\, \\frac{\\mathrm{doses}}{\\mathrm{day}} = 400 \\, \\frac{\\mathrm{mg}}{\\mathrm{day}} $$\n    According to the provided rules, this daily oral levodopa dose is the first term in our sum.\n    $$ \\text{LEDD}_{L} = 400 \\, \\mathrm{mg} $$\n\n2.  **Entacapone Contribution ($\\text{LEDD}_{E}$):**\n    Entacapone is a Catechol-O-methyltransferase (COMT) inhibitor that increases the bioavailability of levodopa. Its contribution is calculated as a factor of the levodopa dose it is co-administered with.\n    The total daily levodopa dose administered with entacapone is $D_{L} = 400 \\, \\mathrm{mg}$. The contribution from entacapone is:\n    $$ \\text{LEDD}_{E} = 0.33 \\times D_{L} = 0.33 \\times 400 \\, \\mathrm{mg} = 132 \\, \\mathrm{mg} $$\n\n3.  **Rasagiline Contribution ($\\text{LEDD}_{R}$):**\n    Rasagiline is a monoamine oxidase-B (MAO-B) inhibitor. The patient's dose is $1 \\, \\mathrm{mg}$ once daily.\n    The problem provides a direct equivalence for this specific dose:\n    $$ \\text{LEDD}_{R} = 100 \\, \\mathrm{mg} $$\n\n4.  **Pramipexole Contribution ($\\text{LEDD}_{P}$):**\n    Pramipexole is a dopamine agonist. The patient takes the immediate-release (IR) formulation at a dose of $0.75 \\, \\mathrm{mg}$ twice daily.\n    The total daily dose of pramipexole, $D_{P}$, is:\n    $$ D_{P} = 0.75 \\, \\frac{\\mathrm{mg}}{\\mathrm{dose}} \\times 2 \\, \\frac{\\mathrm{doses}}{\\mathrm{day}} = 1.5 \\, \\frac{\\mathrm{mg}}{\\mathrm{day}} $$\n    The LEDD contribution is $100$ times this daily dose:\n    $$ \\text{LEDD}_{P} = 100 \\times D_{P} = 100 \\times 1.5 \\, \\mathrm{mg} = 150 \\, \\mathrm{mg} $$\n\n5.  **Total LEDD Calculation:**\n    We now sum the individual contributions to find the total LEDD.\n    $$ \\text{LEDD}_{\\text{total}} = \\text{LEDD}_{L} + \\text{LEDD}_{E} + \\text{LEDD}_{R} + \\text{LEDD}_{P} $$\n    $$ \\text{LEDD}_{\\text{total}} = 400 \\, \\mathrm{mg} + 132 \\, \\mathrm{mg} + 100 \\, \\mathrm{mg} + 150 \\, \\mathrm{mg} $$\n    $$ \\text{LEDD}_{\\text{total}} = 782 \\, \\mathrm{mg} $$\n\n6.  **Final Formatting:**\n    The problem requires the final answer to be rounded to four significant figures. The calculated value, $782$, has three significant figures. To express this with four significant figures, we add a trailing zero after the decimal point.\n    $$ \\text{Final Answer} = 782.0 $$", "answer": "$$\\boxed{782.0}$$", "id": "4880907"}, {"introduction": "A calculated LEDD is not just a number; it is a critical piece of data that informs clinical judgment. This practice problem builds on the basic calculation by presenting a patient with advanced motor complications, requiring you to interpret the LEDD in the context of their symptoms. Making the correct management decision hinges on understanding the relationship between total dopaminergic load, therapeutic benefit, and adverse effects like dyskinesia [@problem_id:4880853].", "problem": "A $67$-year-old person with a $10$-year history of Parkinson’s disease presents with daytime “wearing-off” and prominent peak-dose dyskinesia. Current medications are immediate-release carbidopa/levodopa $25/100$ mg, $1.5$ tablets taken $5$ times daily; controlled-release carbidopa/levodopa $50/200$ mg, $1$ tablet at bedtime; entacapone $200$ mg taken with each levodopa dose; pramipexole $0.35$ mg three times daily; and rasagiline $1$ mg once daily. The motor response remains levodopa-responsive but is complicated by dyskinesia. The clinician wishes to use the levodopa equivalent daily dose (LEDD) to standardize the dopaminergic exposure across the regimen and to guide the next management step.\n\nAssume the following well-tested potency relationships derived from pharmacokinetic and pharmacodynamic observations in Parkinson’s disease:\n- Immediate-release levodopa contributes in a $1:1$ manner to LEDD (that is, $1$ mg immediate-release levodopa contributes $1$ mg LEDD).\n- Controlled-release levodopa provides reduced bioavailability and clinical potency, contributing approximately $0.75$ mg LEDD per $1$ mg of levodopa content.\n- Dopamine agonists have the following approximate levodopa-equivalent potencies: pramipexole $1$ mg $\\approx 100$ mg LEDD; ropinirole $1$ mg $\\approx 20$ mg LEDD; rotigotine $1$ mg $\\approx 30$ mg LEDD.\n- Monoamine oxidase type B (MAO-B) inhibitors have the following approximate levodopa-equivalent potencies: rasagiline $1$ mg $\\approx 100$ mg LEDD; oral selegiline $10$ mg $\\approx 100$ mg LEDD.\n- Catechol-O-methyltransferase (COMT) inhibition with entacapone increases levodopa’s effect by approximately $33\\%$ of the associated levodopa dose (that is, add $0.33 \\times$ the levodopa dose taken with entacapone to the LEDD). For tolcapone or opicapone, the increment is often approximated as $50\\%$.\n\nWhich option best defines LEDD, correctly applies the above potency relationships to compute this patient’s LEDD, and most appropriately situates LEDD in the ensuing clinical decision-making?\n\nA. LEDD is the sum of levodopa-equivalent contributions across all dopaminergic agents, using empirically derived potency ratios. For this regimen: immediate-release levodopa $= 1.5 \\times 100$ mg $\\times 5 = 750$ mg; controlled-release levodopa $= 200$ mg $\\times 0.75 = 150$ mg; entacapone increment $= 0.33 \\times (750 + 200) \\approx 313.5$ mg; pramipexole $= 0.35$ mg $\\times 3 = 1.05$ mg $\\Rightarrow 1.05 \\times 100 \\approx 105$ mg; rasagiline $= 1 \\times 100 = 100$ mg; total LEDD $\\approx 750 + 150 + 313.5 + 105 + 100 \\approx 1{,}420$ mg. Given disabling peak-dose dyskinesia at a high LEDD, avoid further dopaminergic escalation; reduce per-dose levodopa and/or discontinue entacapone to lower LEDD while smoothing delivery (shorter intervals), and consider amantadine for dyskinesia or device-aided therapy if fluctuations persist.\n\nB. LEDD is simply the total milligrams of levodopa administered per day; adjuncts are not counted. For this regimen, LEDD $\\approx 750$ mg $+$ $200$ mg $= 950$ mg. Because this is below typical thresholds for dyskinesia, the appropriate next step is to increase immediate-release levodopa to at least $1{,}200$ mg LEDD to reduce wearing-off.\n\nC. LEDD sums dopaminergic exposures but pramipexole $1$ mg contributes $20$ mg LEDD and rasagiline $1$ mg contributes $10$ mg LEDD; controlled-release levodopa is equivalent to immediate-release, and entacapone’s effect applies only to immediate-release doses. Thus, LEDD $\\approx 750$ mg (immediate-release) $+ 200$ mg (controlled-release) $+ 0.33 \\times 750 \\approx 247.5$ mg $+ (1.05 \\times 20 \\approx 21)$ mg $+ 10$ mg $\\approx 1{,}230$ mg. Because wearing-off is present, add ropinirole to increase LEDD and smooth motor fluctuations.\n\nD. LEDD is the sum of dopaminergic contributions, and entacapone multiplies the entire regimen’s LEDD by $1.33$. Base levodopa LEDD $= 750$ mg $+ 150$ mg $= 900$ mg; pramipexole $= 105$ mg; rasagiline $= 100$ mg; subtotal $= 1{,}105$ mg; after entacapone, LEDD $\\approx 1{,}105 \\times 1.33 \\approx 1{,}470$ mg. Because the LEDD is excessive, first stop rasagiline to reduce LEDD and then increase levodopa to maintain motor control.", "solution": "### Step 1: Extract Givens\n\nThe problem provides the following information about the patient and their medication regimen:\n- Age: $67$ years\n- Disease history: $10$-year history of Parkinson’s disease\n- Clinical presentation: Daytime “wearing-off” and prominent peak-dose dyskinesia.\n- Current medications:\n    - Immediate-release (IR) carbidopa/levodopa $25/100$ mg: $1.5$ tablets, $5$ times daily.\n    - Controlled-release (CR) carbidopa/levodopa $50/200$ mg: $1$ tablet at bedtime.\n    - Entacapone $200$ mg: taken with each levodopa dose.\n    - Pramipexole $0.35$ mg: three times daily.\n    - Rasagiline $1$ mg: once daily.\n\nThe problem also provides a set of explicit assumptions for calculating the Levodopa Equivalent Daily Dose (LEDD):\n- IR levodopa contribution to LEDD: $1:1$ ratio ($1$ mg of levodopa equates to $1$ mg LEDD).\n- CR levodopa contribution to LEDD: Multiplier of $0.75$ ($1$ mg of levodopa equates to $0.75$ mg LEDD).\n- Dopamine Agonist Equivalencies:\n    - Pramipexole: $1$ mg $\\approx 100$ mg LEDD.\n    - Ropinirole: $1$ mg $\\approx 20$ mg LEDD.\n    - Rotigotine: $1$ mg $\\approx 30$ mg LEDD.\n- Monoamine Oxidase type B (MAO-B) Inhibitor Equivalencies:\n    - Rasagiline: $1$ mg $\\approx 100$ mg LEDD.\n    - Oral Selegiline: $10$ mg $\\approx 100$ mg LEDD.\n- Catechol-O-methyltransferase (COMT) Inhibitor Effect:\n    - Entacapone: Increases levodopa's effect by approximately $33\\%$ of the associated levodopa dose (add $0.33 \\times$ [levodopa dose taken with entacapone] to the LEDD).\n\n### Step 2: Validate Using Extracted Givens\n\n- **Scientifically Grounded**: The problem is grounded in the established clinical pharmacology of Parkinson's disease management. The concept of LEDD is a widely used, albeit not perfectly standardized, tool in clinical practice and research to quantify total dopaminergic medication load. The provided conversion factors are within the range of published values, and the problem makes them explicit assumptions, transforming the task into a well-defined calculation and reasoning problem.\n- **Well-Posed**: The problem is well-posed. It provides all necessary data (patient's full medication regimen) and a complete set of rules (potency relationships) to calculate a specific quantity (LEDD). The question is clear, asking for the correct calculation and the most appropriate clinical interpretation. A unique numerical solution for LEDD can be derived from the givens. A minor ambiguity exists in the phrase \"levodopa dose taken with entacapone,\" but one interpretation is strongly supported by the correct option's calculation, and is a common simplification in clinical practice (applying the factor to the total daily levodopa dose for a patient on a COMT inhibitor).\n- **Objective**: The problem is expressed in objective, clinical language. It describes a patient case and provides a set of facts and rules for calculation. There are no subjective or opinion-based statements in the problem setup.\n\n### Step 3: Verdict and Action\n\nThe problem statement is scientifically sound, well-posed, and objective. It presents a standard clinical calculation and reasoning task based on a set of explicit assumptions. The problem is valid. I will proceed to derive the solution.\n\n### Derivation of Solution\n\nThe task is to calculate the patient's total Levodopa Equivalent Daily Dose (LEDD) based on the provided regimen and conversion factors, and then to evaluate the clinical reasoning presented in each option.\n\n1.  **Contribution from Immediate-Release (IR) Carbidopa/Levodopa:**\n    - Levodopa per tablet: $100$ mg.\n    - Tablets per dose: $1.5$.\n    - Doses per day: $5$.\n    - Total daily IR levodopa = $100$ mg/tablet $\\times 1.5$ tablets/dose $\\times 5$ doses/day = $750$ mg.\n    - The conversion factor is $1:1$.\n    - LEDD from IR levodopa = $750$ mg.\n\n2.  **Contribution from Controlled-Release (CR) Carbidopa/Levodopa:**\n    - Levodopa per tablet: $200$ mg.\n    - Tablets per day: $1$.\n    - Total daily CR levodopa = $200$ mg.\n    - The conversion factor is $0.75$.\n    - LEDD from CR levodopa = $200$ mg $\\times 0.75 = 150$ mg.\n\n3.  **Contribution from Pramipexole (Dopamine Agonist):**\n    - Dose: $0.35$ mg.\n    - Doses per day: $3$.\n    - Total daily pramipexole = $0.35$ mg/dose $\\times 3$ doses/day = $1.05$ mg.\n    - The conversion factor is $1$ mg pramipexole $\\approx 100$ mg LEDD.\n    - LEDD from pramipexole = $1.05$ mg $\\times 100$ mg LEDD/mg = $105$ mg.\n\n4.  **Contribution from Rasagiline (MAO-B Inhibitor):**\n    - Dose: $1$ mg.\n    - Doses per day: $1$.\n    - Total daily rasagiline = $1$ mg.\n    - The conversion factor is $1$ mg rasagiline $\\approx 100$ mg LEDD.\n    - LEDD from rasagiline = $1$ mg $\\times 100$ mg LEDD/mg = $100$ mg.\n\n5.  **Contribution from Entacapone (COMT Inhibitor):**\n    - The rule is: \"add $0.33 \\times$ the levodopa dose taken with entacapone to the LEDD\".\n    - The regimen states entacapone is taken \"with each levodopa dose\". This indicates that the presence of entacapone in the regimen is intended to potentiate the levodopa. The \"associated levodopa dose\" is thus the total daily levodopa administered.\n    - Total daily levodopa = Total IR levodopa + Total CR levodopa = $750$ mg $+ 200$ mg $= 950$ mg.\n    - LEDD increment from entacapone = $0.33 \\times 950$ mg $= 313.5$ mg.\n\n6.  **Total LEDD Calculation:**\n    - Total LEDD is the sum of the contributions from each component.\n    - Total LEDD = (LEDD from IR L-dopa) + (LEDD from CR L-dopa) + (LEDD from pramipexole) + (LEDD from rasagiline) + (LEDD increment from entacapone).\n    - Total LEDD = $750$ mg $+ 150$ mg $+ 105$ mg $+ 100$ mg $+ 313.5$ mg.\n    - Total LEDD = $1418.5$ mg.\n    - This is approximately $1420$ mg.\n\n### Option-by-Option Analysis\n\n**A. LEDD is the sum of levodopa-equivalent contributions across all dopaminergic agents, using empirically derived potency ratios. For this regimen: immediate-release levodopa $= 1.5 \\times 100$ mg $\\times 5 = 750$ mg; controlled-release levodopa $= 200$ mg $\\times 0.75 = 150$ mg; entacapone increment $= 0.33 \\times (750 + 200) \\approx 313.5$ mg; pramipexole $= 0.35$ mg $\\times 3 = 1.05$ mg $\\Rightarrow 1.05 \\times 100 \\approx 105$ mg; rasagiline $= 1 \\times 100 = 100$ mg; total LEDD $\\approx 750 + 150 + 313.5 + 105 + 100 \\approx 1{,}420$ mg. Given disabling peak-dose dyskinesia at a high LEDD, avoid further dopaminergic escalation; reduce per-dose levodopa and/or discontinue entacapone to lower LEDD while smoothing delivery (shorter intervals), and consider amantadine for dyskinesia or device-aided therapy if fluctuations persist.**\n- **Definition and Calculation**: The definition of LEDD is correct. The step-by-step calculation precisely matches the derivation above, arriving at a total LEDD of $\\approx 1420$ mg. It correctly applies all conversion factors given in the problem.\n- **Clinical Reasoning**: The patient has \"prominent peak-dose dyskinesia\" and a calculated high LEDD ($\\approx 1420$ mg). The proposed management is clinically sound: avoid increasing dopaminergic load, reduce peak effects by lowering per-dose levodopa or removing the potentiating agent (entacapone), smooth delivery with smaller, more frequent doses, add an antidyskinetic agent (amantadine), and consider advanced therapies (device-aided) for refractory problems. This is the standard, evidence-based approach.\n- **Verdict**: Correct.\n\n**B. LEDD is simply the total milligrams of levodopa administered per day; adjuncts are not counted. For this regimen, LEDD $\\approx 750$ mg $+$ $200$ mg $= 950$ mg. Because this is below typical thresholds for dyskinesia, the appropriate next step is to increase immediate-release levodopa to at least $1{,}200$ mg LEDD to reduce wearing-off.**\n- **Definition and Calculation**: The definition of LEDD is incorrect as it ignores adjunct therapies, contradicting the problem's premise. The calculation, based on this false premise, is arithmetically correct ($750 + 200 = 950$), but does not represent the true LEDD.\n- **Clinical Reasoning**: The reasoning is based on an erroneously low LEDD. The recommendation to increase the levodopa dose would directly worsen the patient's primary complaint of \"prominent peak-dose dyskinesia.\" This is inappropriate and potentially harmful advice.\n- **Verdict**: Incorrect.\n\n**C. LEDD sums dopaminergic exposures but pramipexole $1$ mg contributes $20$ mg LEDD and rasagiline $1$ mg contributes $10$ mg LEDD; controlled-release levodopa is equivalent to immediate-release, and entacapone’s effect applies only to immediate-release doses. Thus, LEDD $\\approx 750$ mg (immediate-release) $+ 200$ mg (controlled-release) $+ 0.33 \\times 750 \\approx 247.5$ mg $+ (1.05 \\times 20 \\approx 21)$ mg $+ 10$ mg $\\approx 1{,}230$ mg. Because wearing-off is present, add ropinirole to increase LEDD and smooth motor fluctuations.**\n- **Calculation**: This option uses several conversion factors that directly contradict the givens in the problem statement. Specifically, it uses incorrect factors for pramipexole, rasagiline, and CR levodopa.\n- **Clinical Reasoning**: The plan to add another dopamine agonist (ropinirole) would increase the LEDD, which is contraindicated in a patient with prominent peak-dose dyskinesia. The primary goal should be to manage the dyskinesia, not simply increase dopaminergic tone.\n- **Verdict**: Incorrect.\n\n**D. LEDD is the sum of dopaminergic contributions, and entacapone multiplies the entire regimen’s LEDD by $1.33$. Base levodopa LEDD $= 750$ mg $+ 150$ mg $= 900$ mg; pramipexole $= 105$ mg; rasagiline $= 100$ mg; subtotal $= 1{,}105$ mg; after entacapone, LEDD $\\approx 1{,}105 \\times 1.33 \\approx 1{,}470$ mg. Because the LEDD is excessive, first stop rasagiline to reduce LEDD and then increase levodopa to maintain motor control.**\n- **Calculation**: The method for applying the entacapone effect is incorrect. The rule is to add an increment based on the *levodopa dose* ($0.33 \\times 950$ mg), not to multiply the *total LEDD* from all drugs by $1.33$. Entacapone does not potentiate dopamine agonists or MAO-B inhibitors.\n- **Clinical Reasoning**: The advice is internally contradictory. It correctly identifies the LEDD as excessive but then suggests stopping one drug (rasagiline) only to increase another (levodopa), which would likely negate the benefit and could worsen peak-dose effects.\n- **Verdict**: Incorrect.", "answer": "$$\\boxed{A}$$", "id": "4880853"}, {"introduction": "The utility of the LEDD concept extends to practical challenges, such as when a patient cannot take their oral medications. This exercise simulates a common hospital scenario requiring the conversion of an oral levodopa regimen to a transdermal dopamine agonist for a patient who is nil per os (NPO). Mastering this type of conversion [@problem_id:4880882] is essential for ensuring continuity of dopaminergic therapy and preventing acute motor deterioration in hospitalized patients.", "problem": "A hospitalized patient with idiopathic Parkinson’s disease is temporarily nil per os (NPO) for a planned procedure. To avoid withdrawal of dopaminergic stimulation, you are instructed to substitute their usual oral levodopa with a transdermal dopamine agonist. The patient’s current total daily levodopa dose is $600$ mg. For this substitution, use the widely applied Levodopa Equivalent Daily Dose (LEDD) framework, which assumes that maintaining total daily dopaminergic stimulation prevents acute motor worsening. You are provided with the following well-tested equivalence used in clinical practice: a rotigotine transdermal patch delivering $4$ mg per $24$ h approximates the dopaminergic effect of $200$ mg of levodopa over the same interval. Assume linear proportionality within this dose range, ignore the contribution of carbidopa, and assume no other dopaminergic agents are being taken.\n\nUsing only these assumptions, compute the single rotigotine patch delivery rate in mg per $24$ h that would approximate the patient’s levodopa exposure. Round your answer to two significant figures and express the final value in mg per $24$ h. Provide your result as a single number.", "solution": "The problem requires the computation of an equivalent dose of a transdermal rotigotine patch for a patient currently treated with oral levodopa. The basis for this conversion is the Levodopa Equivalent Daily Dose (LEDD) framework, which is founded on the principle of maintaining a constant level of dopaminergic stimulation. The problem provides all necessary data and assumptions for this calculation.\n\nFirst, let us define the variables involved.\nLet $D_{LD}$ represent the total daily dose of levodopa in units of mg.\nLet $D_{RTG}$ represent the delivery rate of the rotigotine patch in units of mg per $24$ hours.\n\nThe problem states that there is a linear proportionality between the equivalent doses of levodopa and rotigotine. This relationship can be expressed as a constant ratio:\n$$ \\frac{D_{RTG}}{D_{LD}} = \\text{constant} $$\nThis constant can be determined from the provided clinical equivalence data. The problem states that a rotigotine patch delivering $D_{RTG,ref} = 4$ mg per $24$ h provides dopaminergic stimulation equivalent to $D_{LD,ref} = 200$ mg of levodopa.\n\nWe can set up a proportion to find the unknown rotigotine dose for the patient. Let $D_{LD,patient}$ be the patient's current total daily levodopa dose and $D_{RTG,patient}$ be the target equivalent rotigotine patch delivery rate.\nThe patient's current dose is given as:\n$$ D_{LD,patient} = 600 \\text{ mg} $$\nUsing the principle of proportionality, we can write the following equation:\n$$ \\frac{D_{RTG,patient}}{D_{LD,patient}} = \\frac{D_{RTG,ref}}{D_{LD,ref}} $$\nOur goal is to solve for $D_{RTG,patient}$. Rearranging the equation, we get:\n$$ D_{RTG,patient} = D_{LD,patient} \\times \\frac{D_{RTG,ref}}{D_{LD,ref}} $$\nNow, we substitute the given numerical values into this expression:\n$$ D_{LD,patient} = 600 \\text{ mg} $$\n$$ D_{RTG,ref} = 4 \\text{ mg per 24 h} $$\n$$ D_{LD,ref} = 200 \\text{ mg} $$\nThe calculation proceeds as follows:\n$$ D_{RTG,patient} = (600 \\text{ mg}) \\times \\frac{4 \\text{ mg per 24 h}}{200 \\text{ mg}} $$\nThe units of mg for the levodopa dose cancel out, leaving the desired units of mg per $24$ h for the rotigotine delivery rate.\n$$ D_{RTG,patient} = 600 \\times \\frac{4}{200} \\text{ mg per 24 h} $$\nSimplifying the numerical part of the expression:\n$$ D_{RTG,patient} = 3 \\times 4 \\text{ mg per 24 h} $$\n$$ D_{RTG,patient} = 12 \\text{ mg per 24 h} $$\nThe question requires the final answer to be rounded to two significant figures. The calculated value is $12$. This number, as written, already has two significant figures (the digits $1$ and $2$). Therefore, no further rounding is needed. The required rotigotine patch delivery rate is $12$ mg per $24$ h.", "answer": "$$\\boxed{12}$$", "id": "4880882"}]}